#
Title
1

James Del Rosso, DO: JCAD April 2026 Issue Highlights

2

James Del Rosso, DO, and Joseph Merola, MD, MMSc: What’s New in Cutaneous Lupus Erythematosus

3

James Del Rosso, DO, Diego Dasilva, MD, and Graham Litchman, DO, MS: Management of Severe Nail Psoriasis and Early Psoriatic Arthritis

4

James Del Rosso, DO, and David Cotter, MD, PhD: Clinical Management of Conjunctivitis, Erythema, and Arthralgia in AD

5

James Del Rosso, DO: JCAD March 2026 Issue Highlights

6

Ted Lain, MD, MBA: Long-Term Results of Deuruxolitinib for Alopecia Areata

7

James Del Rosso, DO: JCAD February 2026 Issue Highlights

8

James Del Rosso, DO, and David Cotter, MD, PhD: The Use of Gene-Expression Profile Testing for Effective Atopic Dermatitis Treatment

9

Amy McMichael, MD: Eight-Week Outcomes With Deuruxolitinib in Alopecia Areata

10

Graham Litchman, DO, MS: Understanding Long-Term Treatment Success in a Patient With Psoriasis

11

James Del Rosso, DO: JCAD January 2026 Issue Highlights

12

Aaron Farberg, MD: Real-World Experiences in Alopecia Areata Treatment

13

Arash Mostaghimi, MD, MPH, FAAD: Considerations for the Use of Deuruxolitinib in Patients with Alopecia Areata

14

James Del Rosso, DO: JCAD November 2025 Issue Highlights

15

Extended-cut Podcast—James Del Rosso, DO, and David G. Cotter, MD, PhD: Targeting the IL-31 Neuroimmune Pathway for Treating Prurigo Nodularis

16

James Del Rosso, DO: JCAD October 2025 Issue Highlights

17

David G. Cotter, MD, PhD: The Ideal Patient Candidate for Deuruxolitinib for Patients with Alopecia Areata

18

David G. Cotter, MD, PhD: Utilizing the 31-gene Expression Profile Test in Patients with Melanoma

19

David G. Cotter, MD, PhD: Providing Regrowth of Hair in Patients with Alopecia Areata

20

James Del Rosso, DO: JCAD September 2025 Issue Highlights

21

James Del Rosso, DO: JCAD August 2025 Issue Highlights

22

JCAD Dialogues and Reviews: Updates in Photoprotection and Recent Indication Expansions in Psoriasis and Rosacea

23

James Del Rosso, DO: JCAD June 2025 Issue Highlights

24

Extended-cut Podcast— Naiem Issa, MD, PhD, and Christopher Bunick, MD, PhD: Mechanisms of Dupilumab-associated Arthralgia in Patients with Atopic Dermatitis

25

James Del Rosso, DO: JCAD May 2025 Issue Highlights

26

James Del Rosso, DO: JCAD April 2025 Issue Highlights

27

James Del Rosso, DO: JCAD February 2025 Issue Highlights

28

JCAD Dialogues and Reviews: Highlighting a Vitiligo Roundtable Discussion in JCAD

29

JCAD Dialogues and Reviews: Considerations for Antibiotic Adverse Events

30

James Del Rosso, DO: JCAD January 2025 Issue Highlights

31

James Del Rosso, DO: Dermatology Year in Review 2024

32

JCAD Dialogues and Reviews: Spotlight on a Newly Approved Treatment for Rosacea

33

James Song, MD: Live from Elevate-Derm West—Why Older Immunosuppressant Agents are Still Relevant in 2024

34

James Song, MD: Live from Elevate-Derm West—New Topical and Systemic Agents for Atopic Dermatitis

35

James Del Rosso, DO: New and Exciting Indications for Bimekizumab, Nemolizumab, and Lebrikizumab

36

James Del Rosso, DO: JCAD October 2024 Issue Highlights

37

Leon Kircik, MD: Recent IL-17 Inhibitor Approval for Patients with Psoriasis

38

James Del Rosso, DO: Diagnostic Pearls for Psoriasis

39

Joel Gelfand, MD, MSCE, FAAD: Managing Cardiovascular Risk in Patients with Psoriasis

40

James Del Rosso, DO: Consulting Patients with Psoriasis on Biologic Therapy

41

George Martin, MD: The Utilization of TNF Inhibitors for Psoriasis

42

James Del Rosso, DO: Identifying Appropriate Patients for TNF inhibitors

43

Linda Stein Gold, MD: Updates in Systemic Therapies for Psoriasis

44

George Martin, MD: The Current Role of TNF Inhibitors for Psoriasis

45

Raj Chovatiya, MD, PhD: Mechanisms of Atopic Dermatitis Therapies

46

Nicole Keeter, MSHS, PA-C: Incorporating Topical and Oral Treatments into Your Practice

47

Nicole Keeter, MSHS, PA-C: Focusing on Safety Consideration for the Prescription of JAK Inhibitors

48

James Del Rosso, DO: Topical Treatment for Atopic Dermatitis

49

Peter Lio, MD: The Evolution of Topical JAK Inhibitors

50

James Del Rosso, DO: The Benefits of Topical JAK Inhibitors

51

Lisa Swanson, MD: Things to Consider When Starting Patients on JAK Inhibitors

52

Lisa Swanson, MD: Counseling Patients on JAK Inhibitors

53

Doris Day, MD: The Effect of Stress on Hair Health

54

Raj Chovatiya, MD, PhD: Discussing Atopic Dermatitis Treatment Risks with Patients

55

Douglas DiRuggiero, DMSc, PA-C: Safety of JAK Inhibitors for Atopic Dermatitis

56

Matt Zirwas, MD: Patient Preparatory Guidance for Topical JAK Inhibitors

57

Douglas DiRuggiero, DMSc, PA-C: An Overview of JAK Inhibitors for Atopic Dermatitis

58

Matt Zirwas, MD: An Overview of Janus-kinase (JAK) inhibitors for Atopic Dermatitis